Opus Genetics (IRD)
NASDAQ:IRD
Want to see IRD full AI Analyst Report?
Top Page
Opus Genetics
(NASDAQ:IRD)
Select Model
Select Model
Rating:50Neutral
Price Target:
$4.50
▼(-21.74% Downside)
Action:ReiteratedDate:04/25/26
The score is held back primarily by deteriorating financial performance—declining revenue, large losses, and accelerating cash burn—despite low historical leverage. Offsetting factors include improving technical trend signals and supportive corporate financing actions that may ease near-term funding pressure, though they add leverage and potential dilution.
Positive Factors
Very high gross margin
Gross margins near 100% indicate the company's product/IP economics are highly scalable and lucrative on incremental revenue. Over a multi-quarter horizon, such structural margin leverage means recovered or new sales would flow strongly to operating profit before R&D and SG&A, supporting long-term unit economics for gene therapy products.
Negative Factors
Declining revenue trend
A multi-year revenue decline undermines scale economics and indicates weakening commercial traction or one-time revenue loss. Persisting declines stress margins and increase dependency on funding to sustain R&D. Over 2–6 months, lower recurring revenue constrains reinvestment capacity and heightens execution risk for clinical programs.
Read all positive and negative factors
Positive Factors
Negative Factors
Very high gross margin
Gross margins near 100% indicate the company's product/IP economics are highly scalable and lucrative on incremental revenue. Over a multi-quarter horizon, such structural margin leverage means recovered or new sales would flow strongly to operating profit before R&D and SG&A, supporting long-term unit economics for gene therapy products.
Read all positive factors
Opus Genetics (IRD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$333.45M
Dividend YieldN/A
Average Volume (3M)768.97K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth29.15%
EPS Growth57.69%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.19
Shares Outstanding71,402,470
10 Day Avg. Volume686,996
30 Day Avg. Volume768,965
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)81.49
Price to Sales (P/S)88.10
P/FCF Ratio-35.48
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue20.31
Enterprise Value/Gross Profit35.39
Enterprise Value/Ebitda-6.48
Forecast
1Y Price Target
$10.56Price Target Upside83.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$16.07M
Opus Genetics Business Overview & Revenue Model
Company Description
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine...
How the Company Makes Money
Opus Genetics generates revenue primarily through the development, licensing, and commercialization of its gene therapy treatments and intellectual property targeting inherited retinal diseases. The company may also receive funding through strateg...
Opus Genetics Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
55
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 14.20M | 10.99M | 19.05M | 39.85M | 589.00K |
| Gross Profit | 14.14M | 10.99M | 19.05M | 39.85M | 589.00K |
| EBITDA | -38.60M | -57.52M | -9.97M | 18.22M | -56.69M |
| Net Income | -49.59M | -57.53M | -9.99M | 17.89M | -56.69M |
Balance Sheet | |||||
| Total Assets | 50.24M | 36.86M | 53.95M | 48.99M | 26.08M |
| Cash, Cash Equivalents and Short-Term Investments | 45.09M | 30.32M | 50.52M | 42.68M | 24.75M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 538.00K |
| Total Liabilities | 34.90M | 30.14M | 4.04M | 2.75M | 3.85M |
| Stockholders Equity | 15.35M | 6.72M | 49.91M | 46.24M | 22.22M |
Cash Flow | |||||
| Free Cash Flow | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Operating Cash Flow | -35.25M | -25.58M | -1.11M | 14.31M | -19.37M |
| Investing Cash Flow | 0.00 | 1.21M | 0.00 | 0.00 | -100.00K |
| Financing Cash Flow | 50.02M | 4.19M | 8.98M | 3.79M | 27.61M |
Opus Genetics Technical Analysis
Positive
5.75
Price Trends
4.43
Positive
3.31
Positive
2.41
Positive
Market Momentum
0.38
Negative
70.67
Negative
96.56
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IRD, the sentiment is Positive. The current price of 5.75 is above the 20-day moving average (MA) of 4.96, above the 50-day MA of 4.43, and above the 200-day MA of 2.41, indicating a bullish trend. The MACD of 0.38 indicates Negative momentum. The RSI at 70.67 is Negative, neither overbought nor oversold. The STOCH value of 96.56 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IRD.
Opus Genetics Risk Analysis
Opus Genetics disclosed 56 risk factors in its most recent earnings report. Opus Genetics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Opus Genetics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | $465.47M | -6.90 | -23.98% | ― | 1181.27% | 29.56% | |
56 Neutral | $362.52M | -0.23 | 610.83% | ― | -67.37% | -74.49% | |
53 Neutral | $535.87M | -7.52 | -65.03% | ― | -82.52% | 47.92% | |
53 Neutral | $104.83M | 4.86 | -243.73% | ― | ― | 60.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $333.45M | -25.22 | -452.26% | ― | 29.15% | 57.69% | |
50 Neutral | $245.58M | -4.18 | -46.90% | ― | ― | 77.80% |
* Healthcare Sector Average
IRD
Opus Genetics
4.67
3.72
391.58%
OVID
Ovid Therapeutics
2.69
2.36
722.63%
STTK
Shattuck Labs
7.09
6.10
616.16%
IKT
Inhibikase Therapeutics
1.86
-0.40
-17.70%
SRZN
Surrozen
31.56
20.55
186.65%
BMEA
Biomea Fusion
1.45
-0.65
-30.95%
Opus Genetics Corporate Events
Private Placements and Financing
Opus Genetics Secures $155 Million Senior Note Financing
Positive
Apr 24, 2026
On April 2, 2026, Opus Genetics, Inc. entered into a senior secured note purchase agreement allowing for the issuance of up to $155 million in senior secured notes, with $105 million committed by purchasers and $50 million remaining uncommitted. T...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Opus Genetics Shareholders Approve Governance and Capital Changes
Positive
Apr 22, 2026
At its April 20, 2026 annual meeting, Opus Genetics, Inc. stockholders elected nine directors to one-year terms, ratified Ernst Young, LLP as independent auditor for the 2026 fiscal year, and approved on an advisory basis the compensation of the ...
Business Operations and StrategyExecutive/Board Changes
Opus Genetics Adopts Change-in-Control Executive Bonus Agreements
Positive
Apr 7, 2026
On April 1, 2026, Opus Genetics, Inc. approved Change in Control Bonus Payment Agreements for its chief executive, financial, operating, and scientific and development officers. The agreements provide that the company will reimburse these executiv...
Business Operations and StrategyPrivate Placements and Financing
Opus Genetics Secures Major Non-Dilutive Funding Facility
Positive
Apr 7, 2026
On April 2, 2026, Opus Genetics entered into a senior secured note purchase agreement providing access to up to $155 million in non-dilutive funding from Oberland Capital, with $105 million committed and an initial $35 million tranche expected to ...
Private Placements and FinancingRegulatory Filings and Compliance
Opus Genetics Closes $25 Million Series B Financing
Positive
Feb 19, 2026
On February 13, 2026, Opus Genetics, Inc. entered into a securities purchase agreement with certain investors for a private placement of 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock, which closed on February 18, 2026, raisin...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.